<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293396</url>
  </required_header>
  <id_info>
    <org_study_id>ENM-DA-008</org_study_id>
    <secondary_id>2008-008486-35</secondary_id>
    <nct_id>NCT01293396</nct_id>
  </id_info>
  <brief_title>Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids</brief_title>
  <acronym>HUCKEPACK2</acronym>
  <official_title>Comparison of the Impact of Biphasic Insulin Aspart 30(BiAsp30), Biphasic Insulin Aspart 70 (BiAsp 70) and Insulin Aspart on Postprandial Glucose and Lipid Metabolism During Two Consecutive Meals in Type 2 Diabetics.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate meal-related treatment with either premixed Insulin
      Aspart 30, Aspart 70 and Aspart with regard to postprandial glucose, triglyceride and free
      fatty acids excursions after a standard breakfast and lunch.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Whereas the effects of each of the established types of insulin (BiAsp30, BiAsp70, Insulin
      Aspart) have been shown before, their specific glucose and lipid lowering capacities have so
      far not been investigated in a simulated physiological situation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area over basal for postprandial glucose at each meal alone and in combination</measure>
    <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 min</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area over basal for postprandial triglycerides and free fatty acids at each meal alone and in combination</measure>
    <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum glucose increase at each meal alone and in combination</measure>
    <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum triglyceride increase at each meal alone and in combination</measure>
    <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area over basal for postprandial insulin at each meal alone and in combination</measure>
    <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area over basal for postprandial c-peptide at each meal alone and in combination</measure>
    <time_frame>0,30,60,90,120,180,240,270,300,330,360,420,480,540,600 min</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Biphasic Insulin Aspart 30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Biphasic Insulin Aspart 70</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Aspart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>Patients received insulin aspart before breakfast and before lunch.</description>
    <arm_group_label>Insulin Aspart</arm_group_label>
    <other_name>Novorapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart 30</intervention_name>
    <description>Patients received biphasic insulin aspart 30 before breakfast and before lunch.</description>
    <arm_group_label>Biphasic Insulin Aspart 30</arm_group_label>
    <other_name>Novomix 30</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart 70</intervention_name>
    <description>Patients received biphasic insulin aspart 70 before breakfast and before lunch.</description>
    <arm_group_label>Biphasic Insulin Aspart 70</arm_group_label>
    <other_name>Novomix 70</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type-II Diabetes

          -  BMI &gt; 27 kg/m2

          -  age 35 to 75 years

          -  HbA1c &lt; 8.5%

          -  informed consent

          -  treatment with pre-mixed insulin

          -  stabile dose of insulin for at least 4 weeks

        Exclusion Criteria:

          -  Type-I Diabetes mellitus

          -  HbA1c &gt; 8.5 %

          -  Serum Creatinine &gt; 1.7 mg/dl

          -  ALT or AST &gt; 3x ULN

          -  treatment with sulfonylurea or gliptins

          -  treatment with glitazones

          -  manifest clinical infections

          -  treatment with glucocorticoids or antipsychotic drugs

          -  psychiatric diseases

          -  alcohol abuse

          -  myocardial infarction or stroke within the previous 3 months

          -  surgery within the previous 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R Pieber, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Dept. of Internal Medicine, Div. of Endocrinology and Metabolism, Auenbruggerpl. 15, 8036 Graz, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz, Department for Internal Medicine</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <last_update_submitted>September 22, 2011</last_update_submitted>
  <last_update_submitted_qc>September 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin aspart 30</keyword>
  <keyword>insulin aspart 70</keyword>
  <keyword>insulin aspart</keyword>
  <keyword>postprandial glucose and lipid metabolism</keyword>
  <keyword>consecutive mixed meals</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

